Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 3
1980 10
1981 10
1982 13
1983 9
1984 16
1985 22
1986 15
1987 17
1988 21
1989 31
1990 36
1991 23
1992 31
1993 28
1994 24
1995 41
1996 73
1997 37
1998 59
1999 55
2000 66
2001 77
2002 89
2003 116
2004 146
2005 159
2006 202
2007 218
2008 287
2009 333
2010 355
2011 421
2012 521
2013 616
2014 686
2015 807
2016 839
2017 923
2018 1038
2019 1223
2020 1509
2021 1825
2022 1551
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

13,143 results
Results by year
Filters applied: . Clear all
Page 1
Allergen protease-activated stress granule assembly and gasdermin D fragmentation control interleukin-33 secretion.
Chen W, Chen S, Yan C, Zhang Y, Zhang R, Chen M, Zhong S, Fan W, Zhu S, Zhang D, Lu X, Zhang J, Huang Y, Zhu L, Li X, Lv D, Fu Y, Iv H, Ling Z, Ma L, Jiang H, Long G, Zhu J, Wu D, Wu B, Sun B. Chen W, et al. Among authors: zhu s. Nat Immunol. 2022 Jul;23(7):1021-1030. doi: 10.1038/s41590-022-01255-6. Epub 2022 Jul 6. Nat Immunol. 2022. PMID: 35794369
Shape-Reconfigurable Ferrofluids.
Zhao S, Zhang JY, Fu Y, Zhu S, Shum HC, Liu X, Wang Z, Ye R, Tang BZ, Russell TP, Chai Y. Zhao S, et al. Among authors: zhu s. Nano Lett. 2022 Jul 13;22(13):5538-5543. doi: 10.1021/acs.nanolett.2c01721. Epub 2022 Jun 29. Nano Lett. 2022. PMID: 35766622
Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.
Fujiwara N, Kubota N, Crouchet E, Koneru B, Marquez CA, Jajoriya AK, Panda G, Qian T, Zhu S, Goossens N, Wang X, Liang S, Zhong Z, Lewis S, Taouli B, Schwartz ME, Fiel MI, Singal AG, Marrero JA, Fobar AJ, Parikh ND, Raman I, Li QZ, Taguri M, Ono A, Aikata H, Nakahara T, Nakagawa H, Matsushita Y, Tateishi R, Koike K, Kobayashi M, Higashi T, Nakagawa S, Yamashita YI, Beppu T, Baba H, Kumada H, Chayama K, Baumert TF, Hoshida Y. Fujiwara N, et al. Among authors: zhu s. Sci Transl Med. 2022 Jun 22;14(650):eabo4474. doi: 10.1126/scitranslmed.abo4474. Epub 2022 Jun 22. Sci Transl Med. 2022. PMID: 35731891
Molnupiravir and Its Antiviral Activity Against COVID-19.
Tian L, Pang Z, Li M, Lou F, An X, Zhu S, Song L, Tong Y, Fan H, Fan J. Tian L, et al. Among authors: zhu s. Front Immunol. 2022 Apr 4;13:855496. doi: 10.3389/fimmu.2022.855496. eCollection 2022. Front Immunol. 2022. PMID: 35444647 Free PMC article. Review.
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Liu F, Jiang Y, Gu C; FURLONG investigators. Shi Y, et al. Among authors: zhu s. Lancet Respir Med. 2022 Jun 2:S2213-2600(22)00168-0. doi: 10.1016/S2213-2600(22)00168-0. Online ahead of print. Lancet Respir Med. 2022. PMID: 35662408
13,143 results
You have reached the last available page of results. Please see the User Guide for more information.